Dutasteride vs Finasteride: Clinical Comparison
Both dutasteride and finasteride are equally effective 5-alpha-reductase inhibitors for treating benign prostatic hyperplasia (BPH) with demonstrable prostatic enlargement, showing similar efficacy and comparable safety profiles, though dutasteride demonstrates superior efficacy for androgenic alopecia. 1
For Benign Prostatic Hyperplasia (BPH)
Indications & Patient Selection
Both agents are appropriate only for men with LUTS associated with demonstrable prostatic enlargement 1. Critical selection criteria include:
- Prostate volume >30cc or PSA >1.5 ng/mL for reliable response 2
- Larger glands show more pronounced effects
- Not appropriate for men without prostatic enlargement 1
Common pitfall: Prescribing 5-ARIs to men with LUTS but no prostatic enlargement—these patients will not benefit and should receive alpha-blockers instead 1.
Dosing
- Finasteride: 5 mg once daily for BPH 2
- Dutasteride: 0.5 mg once daily for BPH 3
- Both may be taken with or without food; swallow whole 3
Comparative Efficacy for BPH
The AUA guidelines explicitly state that dutasteride has been shown to be of similar efficacy as finasteride in terms of symptom score improvement, flow-rate improvement, and prevention of disease progression 1. The evidence shows:
- Symptom improvement: Both produce 3-4 point improvement in AUA Symptom Index/IPSS 1, 2
- Flow rate: No clinically significant difference between agents 2
- Prostate volume reduction: Finasteride reduces by ~15-25%, dutasteride by similar amounts 2
- Disease progression: Both reduce risk of acute urinary retention and BPH-related surgery 1, 2
The most recent meta-analysis 4 found dutasteride superior only for maximum urinary flow rate (Qmax improvement of 0.32 mL/s, p=0.04), but showed no significant differences in IPSS reduction, prostate volume, quality of life, or PSA reduction.
Mechanism Differences
- Finasteride: Inhibits only type 2 5-alpha-reductase, reducing DHT by ~70% systemically and ~80% in prostate tissue 2
- Dutasteride: Inhibits both type 1 and 2 5-alpha-reductase, reducing DHT by ~95% systemically and ~94% in prostate tissue 2
Clinical reality: Despite pharmacologic differences, this does not translate to meaningful clinical superiority for BPH, as type 2 5-AR predominates in prostate tissue 2.
Onset of Action
Both have slow onset compared to alpha-blockers—counsel patients on gradual symptom improvement over 6-12 months 2. This is a critical counseling point to prevent premature discontinuation.
For Androgenic Alopecia
Efficacy Comparison
Dutasteride demonstrates superior efficacy to finasteride for androgenic alopecia 5, 6, 7:
- Hair count: Dutasteride increases total hair count by mean difference of 28.57 hairs more than finasteride (p<0.00001) 5
- Global photographic assessment: Dutasteride superior for both vertex and frontal views 5
- Patient satisfaction: Significantly better with dutasteride 5
The most recent real-world evidence from South Korea 7 confirmed dutasteride showed greater improvement in BASP classification than finasteride (adjusted incidence rate ratio: 2.06, p=0.029).
Dosing for Alopecia
- Finasteride: 1 mg daily (standard)
- Dutasteride: 0.5 mg daily (off-label) or intermittent regimens (0.5 mg 2-3 times weekly) 6
Note: Dutasteride is not FDA-approved for androgenic alopecia—this is off-label use 3.
Adverse Effects & Safety
Sexual Dysfunction
Both agents have comparable safety profiles with similar rates of sexual adverse effects 1, 4, 8:
- Decreased libido
- Ejaculatory dysfunction
- Erectile dysfunction
These are reversible and uncommon after the first year of therapy 1. Meta-analyses confirm no significant difference in sexual adverse events between dutasteride and finasteride 4, 8, 5.
Prostate Cancer Risk
Critical consideration: Both agents may increase risk of high-grade prostate cancer 3. The most recent pooled analysis of 15 real-world databases 9 found no significant difference between finasteride and dutasteride in prostate cancer risk (HR=0.87,95% CI: 0.67-1.14, p=0.310).
Neither drug is approved for prostate cancer prevention 3.
PSA Monitoring
Essential monitoring requirement: Both reduce PSA by approximately 50% after 1 year 1, 2, 3:
- Double the measured PSA value after 1 year of therapy to accurately assess for prostate cancer 2
- Any confirmed PSA increase on therapy warrants evaluation, even if within normal range for untreated men 3
Other Precautions
- Pregnancy contraindication: Women who are or may become pregnant must not handle these capsules due to risk to male fetus 3
- Blood donation: Patients should not donate blood until 6 months after last dose 3
Clinical Decision Algorithm
For BPH:
- Confirm prostatic enlargement (volume >30cc or PSA >1.5 ng/mL)
- Choose either finasteride or dutasteride—they are clinically equivalent 1
- Consider combination with alpha-blocker for faster symptom relief and greater long-term benefit 2
- Monitor PSA appropriately (double values after 1 year)
For Androgenic Alopecia:
- Dutasteride is superior to finasteride for hair growth outcomes 5, 7
- Consider starting with dutasteride 0.5 mg daily or 3 times weekly 6
- Counsel on off-label use and 24-week minimum for visible results
- Sexual adverse effects are similar between agents
Bottom line: For BPH, choose based on cost, availability, and patient preference—efficacy is equivalent. For androgenic alopecia, dutasteride provides superior hair growth but is off-label.